Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Merck
AstraZeneca
Colorcon
McKesson

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

TYSABRI Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: TYSABRI
Pharmacology for TYSABRI
Mechanism of ActionIntegrin Receptor Antagonists

US Patents for TYSABRI

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   See Pricing Children\'s Hospital Medical Center (Cincinnati, OH) Westfaelische Wilhelms-Universitaet Muenster (Muenster, DE) 2033-05-14 RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   See Pricing Genentech, Inc. (South San Francisco, CA) 2028-09-16 RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   See Pricing LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   See Pricing Schutzer; Steven E. (New York, NY) 2033-08-15 RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   See Pricing Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2028-04-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for TYSABRI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2019 00006 Denmark   See Pricing PRODUCT NAME: TISAGENLECLEUCEL; REG. NO/DATE: EU/1/18/1297 20180827
300238 Netherlands   See Pricing PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060630
SPC/GB06/030 United Kingdom   See Pricing PRODUCT NAME: NATALIZUMAB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/06/346/001 20060627
SZ 23/2006 Austria   See Pricing PRODUCT NAME: NATALIZUMAB
122006000044 Germany   See Pricing PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.